PARP inhibitors have improved survival of breast cancer patients with BRCA1/2 mutations, but the cancer eventually returns. A Columbia study has now identified a drug that may prevent that relapse.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
Physician-scientist Neil Vasan brings the perspectives he's gained from classical singing and structural biology to his search for new breast cancer treatments.
Columbia University Medical Center (CUMC) is one of 50 institutions selected nationwide from more than 700 applications for a “Provocative Questions” grant from the National Cancer Institute (NCI).